



Media contact:
 Oncology Media Relations
 oncology_media_relations@its.jnj.com

Investor contact:
 Lauren Johnson
 investor-relations@its.jnj.com

U.S. Medical Inquiries:
 +1 800 526-7736

Johnson & Johnson presentations at WCLC 2025:

Lung Cancer	
<i>Rybrevant/Amivantamab</i>	
Poster Presentations	
September 7, 2025 2:55-3:03 PM CEST Abstract PT1.03.06	Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
September 9, 2025 10:00-11:30 AM CEST Abstract P3.12.46	Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: Results From COCOON
September 9, 2025 10:00-11:30 AM CEST Abstract P3.12.72	FIN-EGFR/CNS : Real World Survival and Patient Characteristics of EGFR Mutated NSCLC Patients With CNS Metastases in Finland
September 9, 2025 10:00-11:30 AM CEST Abstract P3.12.32	Long-Term Survival Outcome After First-Line Osimertinib Monotherapy in Advanced/Metastatic NSCLC: Results From LC-SCRUM-Asia
Oral Presentations	
September 9, 2025 11:42-11:47 AM CEST Abstract MA08.03	First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2
September 9, 2025 12:00-12:05 PM CEST Abstract MA08.05	PALOMA-2 : Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) Plus Lazertinib in First-line EGFR-Mutated Advanced NSCLC
September 9, 2025 12:18-12:23 PM CEST Abstract MA07.07	Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC
Early Assets	
Poster Presentations	
September 7, 2025 10:30 AM-12:00 PM CEST Abstract P1.11.14	Depth of Response to Immunotherapy Is Associated With Survival Outcomes in Oligoprogressive NSCLC: A Real-World Data Analysis

September 7, 2025

10:30 AM-12:00 PM CEST

Abstract P1.11.18

Real-World Characterization of Response Kinetics in Patients With Metastatic NSCLC Receiving First-Line Immunotherapy

About RYBREVANT®

RYBREVANT® (amivantamab-vmjw), a fully-human bispecific antibody targeting *EGFR* and MET with immune cell-directing activity, is approved in the [U.S.](#), [Europe](#) and other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. In the subcutaneous formulation, amivantamab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.

RYBREVANT® is approved in the [U.S.](#), [Europe](#) and other markets around the world in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 20 insertion mutations, as detected by an FDA-approved test.

RYBREVANT® is approved in the [U.S.](#), [Europe](#) and other markets around the world in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

RYBREVANT® is approved in the [U.S.](#), [Europe](#) and other markets around the world in combination with chemotherapy (carboplatin-pemetrexed) for the treatment of adult patients with locally advanced or metastatic NSCLC with *EGFR* exon 19 deletions or L858R substitution mutations, whose disease has progressed on or after treatment with an *EGFR* TKI.

Subcutaneous amivantamab is approved in [Europe](#) in combination with LAZCLUZE® for the first-line treatment of adult patients with advanced NSCLC with *EGFR* exon 19 deletions or exon 21 L858R substitution mutations, and as a monotherapy for the treatment of adult patients with advanced NSCLC with activating *EGFR* exon 20 insertion mutations after failure of platinum-based therapy. A Biologics License Application (BLA) was submitted to the U.S. FDA for this indication.

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC³ prefer next-generation sequencing–based strategies over polymerase chain reaction–based approaches for the detection of *EGFR* exon 20 insertion variants. The NCCN Guidelines include:

- Amivantamab-vmjw (RYBREVANT®) plus lazertinib (LAZCLUZE®) as a Category 1 recommendation for first-line therapy in patients with locally advanced or metastatic NSCLC with *EGFR* exon 19 deletions or exon 21 L858R mutations. ^{†‡}
- Amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a Category 1 recommendation for patients with locally advanced or metastatic NSCLC with *EGFR* exon 19 deletions or exon 21 L858R mutations who experienced disease progression after treatment with osimertinib. ^{†‡}
- Amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a Category 1 recommendation for first-line therapy in treatment-naïve patients with newly diagnosed advanced or metastatic *EGFR* exon 20 insertion mutation-positive advanced NSCLC. ^{†‡}
- Amivantamab-vmjw (RYBREVANT®) as a Category 2A recommendation for patients that have progressed on or after platinum-based chemotherapy with or without an immunotherapy and have *EGFR* exon 20 insertion mutation-positive NSCLC. ^{†‡}

For more information, visit: <https://www.RYBREVANT.com>.

About LAZCLUZE®

In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE® (marketed as LECLAZA in South Korea). LAZCLUZE® is an oral, third-generation, brain-penetrant *EGFR* TKI that targets both the T790M mutation and activating *EGFR* mutations while sparing wild-type *EGFR*. An analysis of the efficacy and safety of LAZCLUZE® from the Phase 3 LASER301 study was published in [The Journal of Clinical Oncology](#) in 2023.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at <https://www.jnj.com/> or at www.innovativemedicine.jnj.com. Follow us at [@JNJInnovMed](#). Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE® (lazertinib). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Footnotes

† See the NCCN Guidelines for detailed recommendations, including other treatment options.

‡ The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.

§ The NCCN Content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

###